Regulus Says 11.25M Shares Priced at $4
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of its initial public offering of 11,250,000 shares of its common stock at $4.00 per share. Regulus has also granted the underwriters a 30-day option to purchase up to an additional 1,687,500 shares at the initial public offering price to cover overallotments, if any. Regulus' common stock is scheduled to begin trading on The NASDAQ Global Market on October 4, 2012 under the symbol "RGLS."
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.